Soleus Capital Management L.P. Grows Stock Holdings in Orthofix Medical Inc. (NASDAQ:OFIX)

Soleus Capital Management L.P. grew its position in Orthofix Medical Inc. (NASDAQ:OFIX) by 13.1% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 686,374 shares of the medical device company’s stock after acquiring an additional 79,441 shares during the period. Soleus Capital Management L.P.’s holdings in Orthofix Medical were worth $11,984,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Lazard Asset Management LLC purchased a new position in Orthofix Medical during the 4th quarter valued at about $45,000. R Squared Ltd acquired a new stake in shares of Orthofix Medical during the fourth quarter worth about $50,000. KLP Kapitalforvaltning AS purchased a new position in shares of Orthofix Medical in the fourth quarter valued at approximately $112,000. Tower Research Capital LLC TRC boosted its stake in shares of Orthofix Medical by 120.8% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,458 shares of the medical device company’s stock valued at $148,000 after purchasing an additional 4,627 shares during the period. Finally, State of Wyoming grew its holdings in shares of Orthofix Medical by 206.8% in the fourth quarter. State of Wyoming now owns 9,432 shares of the medical device company’s stock valued at $165,000 after purchasing an additional 6,358 shares in the last quarter. Hedge funds and other institutional investors own 89.76% of the company’s stock.

Orthofix Medical Stock Down 0.5%

OFIX stock opened at $12.14 on Monday. Orthofix Medical Inc. has a fifty-two week low of $10.50 and a fifty-two week high of $20.73. The company’s 50 day moving average price is $14.39 and its 200 day moving average price is $16.78. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.11 and a current ratio of 2.39. The firm has a market capitalization of $473.73 million, a price-to-earnings ratio of -3.88 and a beta of 0.87.

Insider Buying and Selling at Orthofix Medical

In other Orthofix Medical news, CEO Massimo Calafiore purchased 10,000 shares of the business’s stock in a transaction on Friday, May 9th. The shares were bought at an average cost of $12.54 per share, for a total transaction of $125,400.00. Following the completion of the purchase, the chief executive officer now directly owns 234,603 shares in the company, valued at approximately $2,941,921.62. This represents a 4.45% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Jorge Andres Cedron sold 3,816 shares of Orthofix Medical stock in a transaction dated Wednesday, April 16th. The stock was sold at an average price of $13.31, for a total value of $50,790.96. Following the sale, the insider now directly owns 42,500 shares of the company’s stock, valued at $565,675. This trade represents a 8.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 8,475 shares of company stock valued at $128,065. Insiders own 1.30% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on OFIX shares. Roth Mkm reiterated a “buy” rating and set a $22.00 target price on shares of Orthofix Medical in a report on Wednesday, February 26th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $24.00 price objective on shares of Orthofix Medical in a research report on Wednesday, February 26th. Finally, StockNews.com cut Orthofix Medical from a “buy” rating to a “hold” rating in a research note on Wednesday, May 7th.

Orthofix Medical Company Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.